Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

Introduction Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding to various profiles: stability, physiological disease progression and rapid decline. A minority of patients ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF). Maria L.

The project will evaluate the real-world impact of Brainomix’s e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US.

Familial pulmonary fibrosis (FPF) is a devastating interstitial lung disease (ILD) characterized by progressive scarring of lung parenchyma, most commonly manifesting as idiopathic pulmonary fibrosis ...